Exelixis, Inc. (EXEL) Expected to Post Q4 2017 Earnings of $0.10 Per Share
Exelixis, Inc. (NASDAQ:EXEL) – Equities researchers at William Blair raised their Q4 2017 EPS estimates for shares of Exelixis in a research note issued to investors on Monday. William Blair analyst A. Hsieh now forecasts that the biotechnology company will earn $0.10 per share for the quarter, up from their prior forecast of $0.07. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Exelixis’ Q4 2018 earnings at $0.25 EPS.
Several other research analysts have also recently commented on the stock. Needham & Company LLC upped their target price on shares of Exelixis to $33.00 in a research report on Tuesday. Royal Bank Of Canada upped their price target on shares of Exelixis from $33.00 to $39.00 and gave the stock an “outperform” rating in a research note on Tuesday. Stifel Nicolaus reaffirmed a “hold” rating and issued a $26.00 price target on shares of Exelixis in a research note on Tuesday. Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Exelixis in a research note on Monday. Finally, Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Exelixis in a research note on Monday. Six investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $31.00.
ILLEGAL ACTIVITY WARNING: This article was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.dailypolitical.com/2017/10/17/exelixis-inc-exel-expected-to-post-q4-2017-earnings-of-0-10-per-share.html.
Shares of Exelixis (EXEL) traded up 1.4142% during midday trading on Tuesday, reaching $29.4304. 977,012 shares of the company were exchanged. Exelixis has a 52-week low of $10.04 and a 52-week high of $29.58. The stock has a market capitalization of $8.65 billion, a price-to-earnings ratio of 148.6384 and a beta of 1.92. The company’s 50-day moving average price is $26.24 and its 200 day moving average price is $23.95.
Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 EPS for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.02. The firm had revenue of $99.01 million during the quarter, compared to the consensus estimate of $85.27 million. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The firm’s revenue was up 173.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.15) earnings per share.
In related news, insider Michael Morrissey sold 300,000 shares of the stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $26.90, for a total transaction of $8,070,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christopher J. Senner sold 100,000 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $26.79, for a total transaction of $2,679,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 970,152 shares of company stock valued at $25,923,457. Company insiders own 5.10% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. First Quadrant L P CA acquired a new stake in Exelixis during the second quarter valued at approximately $144,000. Meeder Asset Management Inc. acquired a new stake in Exelixis during the first quarter valued at approximately $170,000. Wetherby Asset Management Inc. acquired a new stake in Exelixis during the second quarter valued at approximately $218,000. Caxton Associates LP acquired a new stake in Exelixis during the second quarter valued at approximately $227,000. Finally, Capstone Asset Management Co. acquired a new stake in Exelixis during the second quarter valued at approximately $242,000. 79.20% of the stock is owned by institutional investors and hedge funds.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.